Ipca Laboratories Announces FY26 Financial Results, Recommends 600% Dividend

Ipca Laboratories Announces FY26 Financial Results, Recommends 600% Dividend​

Ipca Laboratories Limited today announced its audited financial results for the fourth quarter (Q4) and the full financial year (FY) ended March 31, 2026. The Board of Directors of the company approved and recommended a dividend of Rs. 6/per share, effective for the period ending March 31, 2026.

During the meeting held on May 29, 2026, the Board also approved the re-appointment of Mr. Prashant Godha (DIN 00012759) as the Executive Director for a further period of five years, effective from August 16, 2026.

The dividend recommendation and the director re-appointment are subject to the approval of the shareholders at the ensuing Annual General Meeting (AGM). The company has set Friday, August 7, 2026, as the record date for members' entitlement to the dividend.

Financial Performance Summary (Q4 FY26 and FY26)​

The company reported strong performance across both standalone and consolidated financials for Q4 FY26 and FY26.

Key financial figures for the year ended March 31, 2026, are summarized below:

Quarterly Highlights (Q4 FY26)​

In the fourth quarter ending March 31, 2026:

• Consolidated Total Income reached Rs. 2,482.22 crores, showing a 9% increase over Q4 FY25.
• Standalone Total Income was Rs. 29.88 crores.
• Consolidated Net Profit after exceptional items was Rs. 309.40 crores, a significant jump from Rs. 65.78 crores in Q4 FY25.

The standalone EBITDA margin stood at 25.27% in Q4 FY26, up from 21.19% in Q4 FY25. The consolidated EBITDA margin was 20.52% in Q4 FY26, compared to 18.24% in Q4 FY25.

Standalone and Consolidated Assets Overview​

Financial statements for the year ended March 31, 2026, showed robust asset growth.

The Group’s total assets stood at 12,370.19 crores as of March 31, 2026, compared to 11,760.55 crores the previous year. Current assets totaled 6,373.61 crores.

Equity and liabilities totaled 9,524.06 crores, with total equity at 8,388.27 crores.

Operational Updates​

The board reported that the financial results are prepared in accordance with Indian Accounting Standards (IND-AS). The financial reporting process included several exceptional items, including:

• Impact of new Labour Codes: Recognized as an exceptional item of Rs. 45.82 crores for FY26.
• Interest settlement of European Commission: This constituted an exceptional income item of Rs. 58.26 crores for FY26.
• Impairment of exposure in Associate: Impairment recorded for the associate Krebs Biochemicals & Industries Ltd. was Rs. 118.90 crores in the previous year.

The company also provided a detailed revenue breakdown for Q4 FY26 and FY26, showing strong growth in both domestic and export segments across Formulations and APIs. For Q4 FY26, the total consolidated revenue from operations was 2,388.48 crores.

IPCALAB Stock Price Movement​

IPCA Laboratories Limited shares today slipped by 4.92% to settle at ₹1524.4. The stock saw a total traded volume of 979,166 shares throughout the day's session.